Aegerion Pharmaceuticals Announces Results From First Year of LOWER Study at AHA Scientific Sessions 2015

Aegerion Pharmaceuticals, Inc.

, a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today presented detailed one-year data from the Company's Lomitapide Observational Worldwide Evaluation Registry (LOWER) study, which showed safety and efficacy results consistent with those observed in the pivotal study of lomitapide in adult patients with homozygous familial hypercholesterolemia (HoFH). There were no new safety signals. Lomitapide, marketed as JUXTAPID(R) capsules in the U.S., is a microsomal triglyceride transfer protein inhibitor indicated in the U.S. as an adjunct to a low-fat diet and other lipid lowering treatments, including apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B) and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with HoFH. Lomitapide is also approved, with a comparable indication, under the brand name LOJUXTA(R) in the European Union. LOWER is a global, long-term, prospective, observational registry of the long-term safety and effectiveness of lomitapide in clinical practice. These and future data from LOWER will provide further information about the long-term safety and effectiveness of lomitapide in a real world setting. At least 300 patients treated with lomitapide in a commercial setting will be followed for a minimum of 10 years. These data were presented in a poster entitled "Lomitapide Observational Worldwide Evaluation Registry (LOWER): One-Year Data" at the 2015 American Heart Association's (AHA) Scientific Sessions in Orlando, Florida. Mark Sumeray, MD, Chief Medical Officer of Aegerion commented, "These new lomitapide data continue to show consistent and clinically meaningful efficacy in patients diagnosed with HoFH. In addition, the safety and tolerability of lomitapide appears consistent with the Phase 3 study that was the basis for JUXTAPID approval from the US Food and Drug Administration and other approvals of lomitapide globally."